Charles River Laboratories International, Inc. · NYSE:CRL

Charles River Laboratories International — FY2025 Earnings Presentation

12 slides from Charles River Laboratories International's earnings presentation, 2026

  1. Slide 1: 4Q25/FY25 Regulation G Financial Reconciliations & Appendix

    4Q25/FY25 Regulation G Financial Reconciliations & Appendix © 2026 Charles River Laboratories International, Inc.

  2. Slide 2: FX Exchange Impact

    FX Exchange (FX) Impact 2025 2026E (% of total revenue) Revenue FX Rates U.S. Dollar 66% ― Euro 19% 1.20 British Pound 6% 1.36 Chinese Yuan (renminbi) 4% 0.14 Canadian Dollar 2% 0.74 Other currencies 3% ― 2

  3. Slide 3: Reconciliation of GAAP to Non-GAAP Selected Business Segment Information

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in thousands, except percentages) Three Months Ended Twelve Months Ended December 27, 2025 December 28, 2024 December 27, 2025 December 28, 2024 Research Models and

  4. Slide 4: Reconciliation of GAAP to Non-GAAP Segment Information (continued)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended Twelve Months Ended December 27, 2025 December 28, 2024 December 27, 2025 December 28, 2024 CONTINUED FROM PRE

  5. Slide 5: Reconciliation of GAAP Earnings (Loss) to Non-GAAP Earnings

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP EARNINGS (LOSS) TO NON-GAAP EARNINGS (UNAUDITED)(1) (in thousands, except per share data) Three Months Ended Twelve Months Ended December 27, 2025 December 28, 2024 December 27, 2025 December 28, 2024 Net income (loss) available t

  6. Slide 6: Reconciliation of GAAP Revenue Growth to Non-GAAP Organic Revenue Growth

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP REVENUE GROWTH (1) TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) Three Months Ended December 27, 2025 Total CRL RMS Segment DSA Segment MS Segment Revenue growth, reported (0.8)% 1.0 % (2.0)% 0.7 % (Increase) decrease due to for

  7. Slide 7: Reconciliation of GAAP to Non-GAAP Revenue and EPS: 2026 Guidance

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP REVENUE AND EARNINGS PER SHARE (EPS) Guidance for the Twelve Months Ended December 26, 2026E 2026 GUIDANCE (1) Revenue growth/(decrease), reported At Least Flat to +1.5% Impact of divestitures/(acquisitions), net 0.0%

  8. Slide 8: Reconciliation of GAAP Tax Rate to Non-GAAP Tax Rate

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TAX RATE TO NON-GAAP TAX RATE (UNAUDITED) (1) (in thousands) Three Months Ended Twelve Months Ended December 27, 2025 September 27, 2025 December 28, 2024 December 27, 2025 December 28, 2024 Income (loss) before income taxes & non

  9. Slide 9: Reconciliation of Gross/Net Leverage Ratio to Adjusted EBITDA

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GROSS/NET LEVERAGE RATIO, INCLUDING GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED) (1) (dollars in thousands, except for per share data) December 27, 2025 December 28, 2024 December 30, 2023 December 31, 2022 December 25, 2021 December

  10. Slide 10: Reconciliation of Free Cash Flow (Non-GAAP)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (UNAUDITED) (1) (in thousands) Three Months Ended Twelve Months Ended December 27, 2025 December 28, 2024 December 27, 2025 December 28, 2024 Net cash provided by operating activities $ 147,520 $ 159,362 $ 737

  11. Slide 11: Reconciliation of GAAP to Non-GAAP Segment Information: Unallocated Corporate Overhead

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended September 27, 2025 Unallocated Corporate Overhead $ (63,833) Add back: Acquisition, integration, and divestitu

  12. Slide 12: © 2026 Charles River Laboratories International, Inc.

    © 2026 Charles River Laboratories International, Inc.

Charles River Laboratories International — FY2025 Earnings Presentation on 6ix